WEST PHARMACEUTICAL SERVICES INC
West Pharmaceutical Services (WST) has a 'Strong Buy' rating from 18 analysts, with a mean price target of $401.65, implying a 10% upside from current levels, according to Barchart.com.
Favorite Annette F (Sr. VP & Chief HR Officer) sold 7,524 shares of WEST PHARMACEUTICAL SERVICES INC (WST) at an average of $355.03 ($345.00–$365.00, $2.67M total) across 3 trades over 2026-09-11 to 2026-09-15 under a Rule 10b5-1 trading plan.
Favorite Annette F (Sr. VP & Chief HR Officer) sold 8,135 shares of WEST PHARMACEUTICAL SERVICES INC (WST) at $340.81 ($2.77M total) across 3 trades on 2026-09-08.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning WST (WEST PHARMACEUTICAL SERVICES INC). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent WST coverage spans financial news, insider activity and earnings.
In the last 30 days, WST insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($5.4M). The most active reporter was Favorite Annette F, Sr. VP & Chief HR Officer, with 6 filings. 50% of those filings were made under pre-arranged Rule 10b5-1 plans.
The upgrade and price target suggest modest upside potential, but no immediate catalyst.
Minor dilution of insider holdings; unlikely to move price materially.
The insider sale may signal a neutral to slightly negative sentiment, but the size is modest relative to market cap.
Mixed reaction; earnings beat but price decline suggests profit‑taking.
Potential price appreciation based on upgraded targets.
AlphAI scores every news story that mentions WST with an AI model for sentiment and relevance, and aggregates insider trades from WEST PHARMACEUTICAL SERVICES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
West Pharmaceutical Services (WST) has a 'Strong Buy' rating from 18 analysts, with a mean price target of $401.65, implying a 10% upside from current levels, according to Barchart.com.
1 min readFavorite Annette F (Sr. VP & Chief HR Officer) sold 7,524 shares of WEST PHARMACEUTICAL SERVICES INC (WST) at an average of $355.03 ($345.00–$365.00, $2.67M total) across 3 trades over 2026-09-11 to 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readFavorite Annette F (Sr. VP & Chief HR Officer) sold 8,135 shares of WEST PHARMACEUTICAL SERVICES INC (WST) at $340.81 ($2.77M total) across 3 trades on 2026-09-08.
1 min readAzenta (AZTA) reported Q2 revenue of $161.2M, up 12% YoY, beating estimates. Repligen (RGEN) reported $204.1M, up 11.9% YoY, with mixed guidance. Charles River Labs (CRL) reported $1.0B, down 2.7% YoY, but beat estimates. West Pharmaceutical (WST) reported $872.3M, up 13.8% YoY, beating estimates. Stocks reacted accordingly.
3 min readWall Street analysts covering West Pharmaceutical (WST) have a consensus 'Strong Buy' rating, with 14 'Strong Buy' ratings, one 'Moderate Buy,' and two 'Holds.' The bullish sentiment has slightly decreased from last month. The mean price target of $401.31 suggests a 14.7% upside, while the highest target at $459 implies a 31.2% potential gain.
1 min readWest Pharmaceutical Services (WST) shares rose 38.1% since late March, outpacing its industry and the S&P 500. The company reported 13% organic revenue growth and 29% adjusted EPS growth in Q2, raised its 2026 outlook to 10-11% organic revenue growth, citing HVP demand, Annex 1 upgrades, GLP-1 exposure, and improving manufacturing productivity after a cyber incident.
4 min readWest Pharmaceutical Services (WST) reported Q2 adjusted EPS of $2.37, up 28.8% and 13.9% above consensus, on revenue of $872.3 million, up 13.8% and above consensus. The company raised 2026 revenue guidance to $3.345B-$3.380B and adjusted EPS to $8.85-$9.05, citing stronger HVP growth and wider margins.
5 min readWest Pharmaceutical Services (WST) reported Q2 organic sales up 12.7% and adjusted EPS up 28.8% to $2.37. HVP components were $424.1M, 49% of revenue, up 18.4% organically. Gross margin rose to 37.7% and operating margin to 22.6%. The article cites 2026 earnings expectations and a 37.1x forward multiple versus peers.
6 min readConestoga Capital Advisors’ Q2 2026 investor letter says small-cap growth led markets, with the Russell 2000 Growth Index up 25.7% in Q2. The letter highlights West Pharmaceutical Services (NYSE:WST), noting a higher stock after another quarter of broad-based growth. It cites 15% organic revenue growth and a reinstated long-term outlook tied to biologics and GLP-1 demand.
4 min readWest Pharmaceutical Services reported higher Q2 2026 sales and earnings, raised its full-year 2026 revenue outlook, completed a US$454.28 million share repurchase, and kept its US$0.22 quarterly dividend. It also expanded a Daikyo Seiko distribution deal via new 10-year agreements, granting West exclusivity outside Japan and expanding Daikyo’s role in Japan.
5 min read
